放疗在老年患者中的使用模式:葡萄牙全国癌症登记数据的启示

IF 2 Q3 HEALTH POLICY & SERVICES
Edna Darlene Rodrigues , Maria José Bento , Rita Calisto , Jéssica Rodrigues , Paulo Almeida , Escarlata López , Laetitia Teixeira
{"title":"放疗在老年患者中的使用模式:葡萄牙全国癌症登记数据的启示","authors":"Edna Darlene Rodrigues ,&nbsp;Maria José Bento ,&nbsp;Rita Calisto ,&nbsp;Jéssica Rodrigues ,&nbsp;Paulo Almeida ,&nbsp;Escarlata López ,&nbsp;Laetitia Teixeira","doi":"10.1016/j.jcpo.2024.100522","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Radiation therapy (RT) will be required by millions of those aged 70 or older by 2040 based on European growth in cancer incidence among this age group.</div></div><div><h3>Purpose</h3><div>This study evaluates the use of external radiotherapy (EBRT) using data from the Portuguese National Cancer Registry (RON), analysing various cancer locations and age groups. A comparative analysis was conducted between actual EBRT utilization and comorbidity-adjusted optimal rates.</div></div><div><h3>Methods</h3><div>Based on RON’s data, cancer diagnoses from January to June 2018 were analysed. Optimal Utilization Proportions (OUP) of EBRT were obtained from European SocieTy for Radiotherapy and Oncology (ESTRO), Health Economics in Radiation Oncology (HERO) project. Actual utilization percentages (AUP) were calculated using national cancer registry data, and a comparative analysis adjusting for comorbidities was conducted.</div></div><div><h3>Results</h3><div>For most cancer locations and age groups, the actual EBRT utilisation fell below the ESTRO-HERO recommendations, with potential untreated patients estimated at 22 % of all new cancer cases across all age groups. Disparities were observed for older patients, such as breast cancer EBRT actual utilisation declining from 68 % to 25 % for patients aged under 70 and 85 or older, respectively. Also, cervix cancer patients aged 75 or older exhibited nearly 100 % optimal EBRT utilisation. Conversely, older patients with bladder and colon cancer had significantly lower RT actual utilisation rates. Comorbidity-adjusted EBRT utilisation rates for lung, rectal, cervix, and breast cancers in patients aged 70–79 did not reached ESTRO-HERO task force recommended rates. The actual EBRT usage in Portugal failed to meet the comorbidity-adjusted optimal utilisation rate for all cancer locations and age groups. Nevertheless, Portuguese actual EBRT for rectal and prostate cancer, exceeded the actual rates in Australian cohort.</div></div><div><h3>Conclusion</h3><div>While EBRT is essential for older adults with cancer, disparities and suboptimal utilization highlight opportunities for improving cancer care provision.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100522"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Utilisation patterns of radiotherapy among older patients: Insights from Portuguese National Cancer Registry data\",\"authors\":\"Edna Darlene Rodrigues ,&nbsp;Maria José Bento ,&nbsp;Rita Calisto ,&nbsp;Jéssica Rodrigues ,&nbsp;Paulo Almeida ,&nbsp;Escarlata López ,&nbsp;Laetitia Teixeira\",\"doi\":\"10.1016/j.jcpo.2024.100522\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Radiation therapy (RT) will be required by millions of those aged 70 or older by 2040 based on European growth in cancer incidence among this age group.</div></div><div><h3>Purpose</h3><div>This study evaluates the use of external radiotherapy (EBRT) using data from the Portuguese National Cancer Registry (RON), analysing various cancer locations and age groups. A comparative analysis was conducted between actual EBRT utilization and comorbidity-adjusted optimal rates.</div></div><div><h3>Methods</h3><div>Based on RON’s data, cancer diagnoses from January to June 2018 were analysed. Optimal Utilization Proportions (OUP) of EBRT were obtained from European SocieTy for Radiotherapy and Oncology (ESTRO), Health Economics in Radiation Oncology (HERO) project. Actual utilization percentages (AUP) were calculated using national cancer registry data, and a comparative analysis adjusting for comorbidities was conducted.</div></div><div><h3>Results</h3><div>For most cancer locations and age groups, the actual EBRT utilisation fell below the ESTRO-HERO recommendations, with potential untreated patients estimated at 22 % of all new cancer cases across all age groups. Disparities were observed for older patients, such as breast cancer EBRT actual utilisation declining from 68 % to 25 % for patients aged under 70 and 85 or older, respectively. Also, cervix cancer patients aged 75 or older exhibited nearly 100 % optimal EBRT utilisation. Conversely, older patients with bladder and colon cancer had significantly lower RT actual utilisation rates. Comorbidity-adjusted EBRT utilisation rates for lung, rectal, cervix, and breast cancers in patients aged 70–79 did not reached ESTRO-HERO task force recommended rates. The actual EBRT usage in Portugal failed to meet the comorbidity-adjusted optimal utilisation rate for all cancer locations and age groups. Nevertheless, Portuguese actual EBRT for rectal and prostate cancer, exceeded the actual rates in Australian cohort.</div></div><div><h3>Conclusion</h3><div>While EBRT is essential for older adults with cancer, disparities and suboptimal utilization highlight opportunities for improving cancer care provision.</div></div>\",\"PeriodicalId\":38212,\"journal\":{\"name\":\"Journal of Cancer Policy\",\"volume\":\"43 \",\"pages\":\"Article 100522\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213538324000560\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH POLICY & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538324000560","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

导言:目的:本研究利用葡萄牙国家癌症登记处(RON)的数据评估了体外放射治疗(EBRT)的使用情况,分析了各种癌症的发病部位和年龄组。方法:根据葡萄牙国家癌症登记处的数据,对不同癌症部位和年龄组的外放射治疗(EBRT)使用情况进行了评估:根据 RON 的数据,对 2018 年 1 月至 6 月的癌症诊断进行了分析。EBRT的最佳利用率(OUP)来自欧洲放射治疗和肿瘤学协会(ESTRO)的放射肿瘤学卫生经济学(HERO)项目。使用国家癌症登记数据计算了实际利用率(AUP),并根据合并症进行了比较分析:结果:对于大多数癌症部位和年龄组,EBRT 的实际使用率低于 ESTRO-HERO 的建议值,估计所有年龄组潜在的未治疗患者占所有新发癌症病例的 22%。老年患者的使用率存在差异,例如 70 岁以下和 85 岁或以上的乳腺癌患者 EBRT 的实际使用率分别从 68% 降至 25%。此外,75 岁或以上的宫颈癌患者的 EBRT 最佳利用率接近 100%。相反,老年膀胱癌和结肠癌患者的 RT 实际使用率明显较低。对于 70-79 岁的肺癌、直肠癌、宫颈癌和乳腺癌患者,经合并症调整后的 EBRT 利用率未达到 ESTRO-HERO 工作组的建议利用率。葡萄牙的 EBRT 实际使用率未能达到所有癌症部位和年龄组的合并症调整后最佳使用率。不过,葡萄牙对直肠癌和前列腺癌的实际 EBRT 率超过了澳大利亚队列的实际使用率:虽然 EBRT 对患有癌症的老年人至关重要,但差异和未达到最佳利用率凸显了改善癌症护理服务的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Utilisation patterns of radiotherapy among older patients: Insights from Portuguese National Cancer Registry data

Introduction

Radiation therapy (RT) will be required by millions of those aged 70 or older by 2040 based on European growth in cancer incidence among this age group.

Purpose

This study evaluates the use of external radiotherapy (EBRT) using data from the Portuguese National Cancer Registry (RON), analysing various cancer locations and age groups. A comparative analysis was conducted between actual EBRT utilization and comorbidity-adjusted optimal rates.

Methods

Based on RON’s data, cancer diagnoses from January to June 2018 were analysed. Optimal Utilization Proportions (OUP) of EBRT were obtained from European SocieTy for Radiotherapy and Oncology (ESTRO), Health Economics in Radiation Oncology (HERO) project. Actual utilization percentages (AUP) were calculated using national cancer registry data, and a comparative analysis adjusting for comorbidities was conducted.

Results

For most cancer locations and age groups, the actual EBRT utilisation fell below the ESTRO-HERO recommendations, with potential untreated patients estimated at 22 % of all new cancer cases across all age groups. Disparities were observed for older patients, such as breast cancer EBRT actual utilisation declining from 68 % to 25 % for patients aged under 70 and 85 or older, respectively. Also, cervix cancer patients aged 75 or older exhibited nearly 100 % optimal EBRT utilisation. Conversely, older patients with bladder and colon cancer had significantly lower RT actual utilisation rates. Comorbidity-adjusted EBRT utilisation rates for lung, rectal, cervix, and breast cancers in patients aged 70–79 did not reached ESTRO-HERO task force recommended rates. The actual EBRT usage in Portugal failed to meet the comorbidity-adjusted optimal utilisation rate for all cancer locations and age groups. Nevertheless, Portuguese actual EBRT for rectal and prostate cancer, exceeded the actual rates in Australian cohort.

Conclusion

While EBRT is essential for older adults with cancer, disparities and suboptimal utilization highlight opportunities for improving cancer care provision.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Cancer Policy
Journal of Cancer Policy Medicine-Health Policy
CiteScore
2.40
自引率
7.70%
发文量
47
审稿时长
65 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信